Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.8.0.1
Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Net sales $ 144,613 $ 130,581
Operating income 26,031 29,156
Amortization of acquisition related intangible assets (11,379)  
Corporate general, selling, and administrative expenses (58,289) (45,424)
Acquisition Related [Member]    
Corporate general, selling, and administrative expenses (2,432) (1,582)
Operating Segments [Member]    
Operating income 53,488 48,992
Intersegment Eliminations [Member]    
Net sales (89) (12)
Segment Reconciling Items [Member]    
Costs recognized on sale of acquired inventory (318) (1,344)
Amortization of acquisition related intangible assets (11,379) (10,188)
Acquisition related expenses (9,533) (3,532)
Stock based compensation (3,795) (3,190)
Biotechnology [Member] | Operating Segments [Member]    
Net sales 95,076 86,787
Operating income 44,603 42,480
Protein Platforms [Member] | Operating Segments [Member]    
Net sales 24,640 19,573
Operating income 3,056 209
Diagnostics [Member] | Operating Segments [Member]    
Net sales 24,986 24,233
Operating income $ 5,829 $ 6,303